Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...

In a significant leap forward for successful cancer surgery, researchers at the University of Missouri and collaborators have ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most ...

CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic ...

Circulating tumor DNA (ctDNA) testing changes occur nearly every year, making consistent updates to National Comprehensive Cancer Network (NCCN) guidelines important for clinicians to make decisions ...

The Innovation Center of NanoMedicine has summarized the results of its collaborative research with Professor Kanjiro ...

Denver Broncos' passing game coordinator Zach Grossi faced the toughest obstacle of his life in 2024, and he opened up on ...

Thanks to a machine that’s new to the area, the radiation process has become shorter, less consequential and more effective.

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

Prostate cancer is one of the most common cancers and the second leading cause of cancer-related death in men worldwide. However, the mechanisms controlling the early stages of prostate cancer ...

Dr. Omar Llaguna, specialist in surgical oncology, programs a HistoSonics medical device for targeting a medium that mimics a liver tumor in a human body to demonstrate how a histotripsy procedure ...

In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.